Levodopa/Benserazide Pch (Benserazide, Levodopa)

Levodopa is a precursor of dopamine that crosses the blood‑brain barrier. Once inside the central nervous system it is converted to dopamine, replenishing the neurotransmitter that is deficient in Parkinsonian disorders. Benserazide blocks peripheral conversion, allowing more levodopa to reach the brain.

The exact dose is individualized and set by the prescribing clinician based on disease severity, patient age, response to therapy and any co‑existing medical conditions. Dosage adjustments are made during follow‑up visits to achieve optimal symptom control while minimising side effects.

Safety data for Levodopa/Benserazide in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and only under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Levodopa/Benserazide is often considered the most effective oral therapy for motor symptoms because it directly restores dopamine. Compared with dopamine agonists, it usually provides stronger symptom relief but may have a higher incidence of motor complications. Combination with other agents, such as MAO‑B inhibitors, can be used to fine‑tune therapy.

Store the product at room temperature, preferably below 25 °C. Keep it in the original blister or bottle, protect it from moisture, heat and direct sunlight. Do not refrigerate or freeze the tablets, as this could affect their stability.

Levodopa/Benserazide is taken orally, usually with a glass of water. It may be prescribed to be taken with or without food, depending on the prescriber's guidance. Tablets should be swallowed whole and not split unless the prescriber specifically advises otherwise.

Serious adverse events include dyskinesia (involuntary movements), hallucinations or psychosis, severe orthostatic hypotension, neuroleptic malignant syndrome and cardiac arrhythmias. Patients should be monitored closely for these reactions, and any sudden changes in mental status or cardiovascular symptoms should prompt immediate medical evaluation.

Levodopa/Benserazide is contraindicated in patients with known hypersensitivity to levodopa, benserazide or any excipients. It should also be avoided in individuals taking non‑selective MAO inhibitors or those with narrow‑angle glaucoma, as the drug may exacerbate intra‑ocular pressure.